Windlas Biotech Ltd (WINDLAS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003519,
    "name": "Windlas Biotech",
    "stock_name": "Windlas Biotech",
    "full_name": "Windlas Biotech Ltd",
    "name_url": "stocks-analysis/windlas-biotech",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "840.00",
    "chg": -12.4,
    "chgp": "-1.45%",
    "dir": -1,
    "prev_price": "852.40",
    "mcapval": "1,785.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543329,
    "symbol": "WINDLAS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0H5O01029",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "35.81 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/windlas-biotech-1003519-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Windlas Biotech overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-windlas-biotech-overvalued-or-undervalued-3745661",
        "imagepath": "",
        "date": "2025-12-04 08:45:22",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics and Financial Health</strong></p>\n<p>Windlas Biotech trades at a price-to-earnings (PE) ratio of approximately 24.8, which places it in the mid-range relative to its industry peers. Its price-to-book value stands at 3.13, indicating that the market values the company at over three times its net asset value. The enterprise value to EBITDA ratio of 13.7 suggests a moderate premium, reflecting expectations of steady earnings before interest, taxes, depreciation, and amortisation.</p>\n<p>Return on capital employed (ROCE) is a robust 24.6%, signalling efficient use of capital to generate profits, while return on equity (ROE) at 12.6% is respectable but not exceptional. The dividend yield is modest at 0.73%, which may appeal less to income-focused investors but aligns with growth..."
      },
      {
        "title": "Windlas Biotech Sees Revision in Market Assessment Amidst Challenging Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/windlas-biotech-downgraded-to-sell-by-marketsmojo-amid-weak-performance-3736827",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_mojoScore_3736827.png",
        "date": "2025-11-29 17:52:31",
        "description": "Windlas Biotech has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters amid a backdrop of subdued stock performance and sector challenges. This adjustment highlights evolving perspectives on the company’s financial health, valuation, and technical outlook within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Windlas Biotech Faces Bearish Technical Trends Amidst Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotechs-technical-trend-shifts-from-mildly-bearish-to-bearish-amid-stock-decline-3696635",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_technicaldot_3696635.png",
        "date": "2025-11-13 08:10:53",
        "description": "Windlas Biotech, a small-cap pharmaceutical company, has faced a challenging year with a return of -16.53%, contrasting with the Sensex's gain. Technical indicators suggest a bearish sentiment, yet the company has shown resilience with a notable 247.73% return over the past three years, outperforming the Sensex significantly."
      },
      {
        "title": "Windlas Biotech Forms Death Cross, Signaling Potential Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-forms-death-cross-signaling-potential-bearish-trend-ahead-3693092",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_dealthcross_3693092.png",
        "date": "2025-11-12 18:00:58",
        "description": "Windlas Biotech has recently encountered a technical event known as a Death Cross, indicating potential market sentiment shifts. The stock has declined 0.51%, contributing to a one-year performance of -16.53%, while its market capitalization is Rs 1,779.00 crore, with a P/E ratio lower than the industry average."
      },
      {
        "title": "Why is Windlas Biotech falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-windlas-biotech-fallingrising-3681620",
        "imagepath": "",
        "date": "2025-11-08 00:10:35",
        "description": "As of 07-Nov, Windlas Biotech Ltd is experiencing a decline in its stock price, currently at Rs 867.80, which represents a decrease of Rs 56.2 or 6.08%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 9.66% during this period. It opened with a loss of 2.6% today and reached an intraday low of Rs 855, reflecting a 7.47% drop. In terms of performance over the past week, the stock has decreased by 7.89%, while its year-to-date return stands at a negative 16.03%. Despite positive quarterly results showing the highest net sales and operating profit margins, the stock's overall performance has been hindered by poor long-term growth and significant underperformance relative to the broader market.\n\nIn the broader market context, Windlas Biotech's recent performance contrasts sharply with the Sensex, which has gained 1.57% over the past month. ..."
      },
      {
        "title": "Are Windlas Biotech latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-windlas-biotech-latest-results-good-or-bad-3680569",
        "imagepath": "",
        "date": "2025-11-07 19:26:39",
        "description": "Windlas Biotech's latest financial results present a mixed picture of operational performance. The company reported record revenue of ₹222.40 crores in Q2 FY26, reflecting a sequential growth of 5.86% and an 18.93% increase year-on-year. This consistent revenue momentum has been evident over the past seven quarters, indicating strong demand for its CDMO services.\n\nHowever, profitability metrics have not kept pace with revenue growth. The operating margin, which stood at 12.84%, showed only a marginal improvement from the previous quarter, while the PAT margin compressed to 8.00%, down from 8.41% in Q1 FY26. This suggests challenges in translating topline growth into bottom-line expansion, raising concerns about operational efficiency and cost management.\n\nThe financial data indicates that employee costs surged significantly, outpacing revenue growth, which contributed to the margin compression. Additionally..."
      },
      {
        "title": "Windlas Biotech Hits Day Low at Rs 863.2 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-hits-day-low-at-rs-8632-amid-price-pressure-3679991",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_priceRelatedfactors_3679991.png",
        "date": "2025-11-07 15:03:53",
        "description": "Windlas Biotech has faced a notable decline, losing 7.35% on November 7, 2025. The stock has underperformed the sector and broader market trends, trading below key moving averages. Year-to-date, it has decreased by 14.96%, contrasting sharply with the Sensex's gain of 6.46%."
      },
      {
        "title": "Windlas Biotech Faces Technical Shift Amidst Mixed Financial Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/windlas-biotech-stock-downgraded-from-hold-to-sell-by-marketsmojo-3678807",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_mojoScore_3678807.png",
        "date": "2025-11-07 08:28:33",
        "description": "Windlas Biotech, a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a shift in its technical indicators, moving to a mildly bearish trend. Despite a positive quarterly financial performance, the stock has underperformed compared to the broader market over the past year."
      },
      {
        "title": "Windlas Biotech Faces Mixed Technical Trends Amidst Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotechs-technical-trend-shifts-from-sideways-to-mildly-bearish-amid-stock-decline-3678705",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_technicaldot_3678705.png",
        "date": "2025-11-07 08:09:57",
        "description": "Windlas Biotech, a small-cap pharmaceutical company, has experienced a challenging year with a return of -17.01%, contrasting with the Sensex's modest gain. Despite recent fluctuations, the company has shown resilience with a significant 284.38% return over the past three years, outperforming the Sensex during that period."
      }
    ],
    "total": 242,
    "sid": "1003519",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/windlas-biotech-1003519"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "29-Jan-2026",
      "details": "Schedule of Conference Call to discuss financial performance for the quarter and nine months ended December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Notice Of The Board Meeting Scheduled To Be Held On Thursday February 5 2026",
      "datetime": "28-Jan-2026",
      "details": "Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 inter alia to consider and approve To inter alia consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "22-Jan-2026",
      "details": "Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Windlas Biotech Ltd has declared <strong>116%</strong> dividend, ex-date: 21 Jul 25",
          "dt": "2025-07-21",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Windlas Biotech overvalued or undervalued?

2025-12-04 08:45:22

Valuation Metrics and Financial Health Windlas Biotech trades at a price-to-earnings (PE) ratio of approximately 24.8, which places it in the mid-range relative to its industry peers. Its price-to-book value stands at 3.13, indicating that the market values the company at over three times its net asset value. The enterprise value to EBITDA ratio of 13.7 suggests a moderate premium, reflecting expectations of steady earnings before interest, taxes, depreciation, and amortisation. Return on capital employed (ROCE) is a robust 24.6%, signalling efficient use of capital to generate profits, while return on equity (ROE) at 12.6% is respectable but not exceptional. The dividend yield is modest at 0.73%, which may appeal less to income-focused investors but aligns with growth...

Windlas Biotech Sees Revision in Market Assessment Amidst Challenging Performance

2025-11-29 17:52:31

Windlas Biotech has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters amid a backdrop of subdued stock performance and sector challenges. This adjustment highlights evolving perspectives on the company’s financial health, valuation, and technical outlook within the Pharmaceuticals & Biotechnology sector.

Windlas Biotech Faces Bearish Technical Trends Amidst Market Challenges

2025-11-13 08:10:53

Windlas Biotech, a small-cap pharmaceutical company, has faced a challenging year with a return of -16.53%, contrasting with the Sensex's gain. Technical indicators suggest a bearish sentiment, yet the company has shown resilience with a notable 247.73% return over the past three years, outperforming the Sensex significantly.

Windlas Biotech Forms Death Cross, Signaling Potential Bearish Trend Ahead

2025-11-12 18:00:58

Windlas Biotech has recently encountered a technical event known as a Death Cross, indicating potential market sentiment shifts. The stock has declined 0.51%, contributing to a one-year performance of -16.53%, while its market capitalization is Rs 1,779.00 crore, with a P/E ratio lower than the industry average.

Why is Windlas Biotech falling/rising?

2025-11-08 00:10:35

As of 07-Nov, Windlas Biotech Ltd is experiencing a decline in its stock price, currently at Rs 867.80, which represents a decrease of Rs 56.2 or 6.08%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 9.66% during this period. It opened with a loss of 2.6% today and reached an intraday low of Rs 855, reflecting a 7.47% drop. In terms of performance over the past week, the stock has decreased by 7.89%, while its year-to-date return stands at a negative 16.03%. Despite positive quarterly results showing the highest net sales and operating profit margins, the stock's overall performance has been hindered by poor long-term growth and significant underperformance relative to the broader market. In the broader market context, Windlas Biotech's recent performance contrasts sharply with the Sensex, which has gained 1.57% over the past month. ...

Are Windlas Biotech latest results good or bad?

2025-11-07 19:26:39

Windlas Biotech's latest financial results present a mixed picture of operational performance. The company reported record revenue of ₹222.40 crores in Q2 FY26, reflecting a sequential growth of 5.86% and an 18.93% increase year-on-year. This consistent revenue momentum has been evident over the past seven quarters, indicating strong demand for its CDMO services. However, profitability metrics have not kept pace with revenue growth. The operating margin, which stood at 12.84%, showed only a marginal improvement from the previous quarter, while the PAT margin compressed to 8.00%, down from 8.41% in Q1 FY26. This suggests challenges in translating topline growth into bottom-line expansion, raising concerns about operational efficiency and cost management. The financial data indicates that employee costs surged significantly, outpacing revenue growth, which contributed to the margin compression. Additionally...

Windlas Biotech Hits Day Low at Rs 863.2 Amid Price Pressure

2025-11-07 15:03:53

Windlas Biotech has faced a notable decline, losing 7.35% on November 7, 2025. The stock has underperformed the sector and broader market trends, trading below key moving averages. Year-to-date, it has decreased by 14.96%, contrasting sharply with the Sensex's gain of 6.46%.

Windlas Biotech Faces Technical Shift Amidst Mixed Financial Performance Indicators

2025-11-07 08:28:33

Windlas Biotech, a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a shift in its technical indicators, moving to a mildly bearish trend. Despite a positive quarterly financial performance, the stock has underperformed compared to the broader market over the past year.

Windlas Biotech Faces Mixed Technical Trends Amidst Market Challenges

2025-11-07 08:09:57

Windlas Biotech, a small-cap pharmaceutical company, has experienced a challenging year with a return of -17.01%, contrasting with the Sensex's modest gain. Despite recent fluctuations, the company has shown resilience with a significant 284.38% return over the past three years, outperforming the Sensex during that period.

View All News